0      0

HiddenEval001 - Expert Perspectives in Advanced Prostate Cancer

  • Compare the benefits and risks associated with new systemic agents for the treatment of castrate resistant prostate cancer (CRPC) including immunotherapy, secondary hormonal agents, chemotherapy, and radiopharmaceuticals.
  • Assess current treatment guidelines regarding appropriate sequencing of new therapeutic approaches for the treatment of CRPC.
  • Appraise individual patient disease characteristics: recognize, understand, and manage disease and treatment related complications associated with CRPC.
  • Formulate appropriate care plans and provide counsel for patients and their families.